Thane Wettig
Vorstandsvorsitzender bei FIBROGEN, INC.
Vermögen: 458 547 $ am 30.04.2024
Aktive Positionen von Thane Wettig
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
FIBROGEN, INC. | Direktor/Vorstandsmitglied | 02.10.2023 | - |
Vorstandsvorsitzender | 23.07.2023 | - | |
Corporate Officer/Principal | 22.06.2020 | 23.07.2023 |
Karriereverlauf von Thane Wettig
Ehemalige bekannte Positionen von Thane Wettig
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Lilly Diabetes | Corporate Officer/Principal | 01.01.1990 | 01.01.2009 |
Vertrieb & Marketing | 01.01.2009 | - | |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Corporate Officer/Principal | 01.01.2018 | - |
Ausbildung von Thane Wettig
Washington University in St. Louis | Masters Business Admin |
Statistik
International
Vereinigte Staaten | 5 |
Operativ
Corporate Officer/Principal | 3 |
Masters Business Admin | 1 |
Undergraduate Degree | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
FIBROGEN, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
Lilly Diabetes |
- Börse
- Insiders
- Thane Wettig
- Erfahrung